Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

NCT00567398
completedphase_4

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

NCT00567489
terminatedphase_2

Heart Failure and Peritoneal Ultrafiltration

NCT00368641
completedphase_4

Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis

NCT01228279

Clinical Trials (4)

Showing 4 of 4 trials
NCT00567398Phase 3

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

Completed
NCT00567489Phase 4

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

Completed
NCT00368641Phase 2

Heart Failure and Peritoneal Ultrafiltration

Terminated
NCT01228279Phase 4

Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4